Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Stock

Equities

603392

CNE100004090

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-05-21 pm EDT 5-day change 1st Jan Change
65.63 CNY -0.35% Intraday chart for Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. -0.61% -12.64%
Sales 2024 * 4.84B 669M Sales 2025 * 7.23B 998M Capitalization 83.23B 11.5B
Net income 2024 * 2.55B 353M Net income 2025 * 3.47B 479M EV / Sales 2024 * 16.1 x
Net cash position 2024 * 5.27B 728M Net cash position 2025 * 5.25B 726M EV / Sales 2025 * 10.8 x
P/E ratio 2024 *
37.2 x
P/E ratio 2025 *
27.2 x
Employees 3,843
Yield 2024 *
0.22%
Yield 2025 *
0.29%
Free-Float 18.23%
More Fundamentals * Assessed data
Dynamic Chart
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Wantai Biological's Phase 3 Trials for Nine-Valent HPV Vaccine Yields Performed 'As Expected' MT
Wantai BioPharm's 2023 Profit Drops 74% on Revenue Drop; Shares Slump 3% MT
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Wantai Biological Pharmacy Predicts Up to 75% Profit Decline in 2023 MT
Sinovac Halts Production of COVID-19 Vaccine as Demand Wanes MT
Zhifei Biological Falls After Merck Secures Nod to Market HPV Vaccine in China MT
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. announces an Equity Buyback for CNY 400 million worth of its shares. CI
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. authorizes a Buyback Plan. CI
Wantai Biological Pharmacy's Profit Drops 36.8% in H1 MT
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Wantai Biological Pharmacy’s Profit Slides 6.5% in Q1 as Revenue Falls 9% MT
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Wantai BioPharm Enrolls First Subjects for Pneumonia Vaccine Trial MT
More news
1 day-0.35%
1 week-0.61%
Current month-3.88%
1 month-1.37%
3 months-2.55%
6 months+35.60%
Current year-12.64%
More quotes
1 week
64.31
Extreme 64.31
67.32
1 month
63.00
Extreme 63
70.81
Current year
47.62
Extreme 47.62
88.00
1 year
40.14
Extreme 40.14
88.00
3 years
40.14
Extreme 40.14
147.67
5 years
4.43
Extreme 4.4335
147.67
10 years
4.43
Extreme 4.4335
147.67
More quotes
Managers TitleAgeSince
Director of Finance/CFO 53 07-12-31
Chairman 60 96-12-31
Chief Administrative Officer 42 06-12-31
Members of the board TitleAgeSince
Chairman 60 96-12-31
66 -
Chairman 39 18-04-12
More insiders
Date Price Change Volume
24-05-22 65.63 -0.35% 2,977,843
24-05-21 65.86 -0.99% 2,095,104
24-05-20 66.52 -0.14% 3,135,717
24-05-17 66.61 +1.03% 2,491,434
24-05-16 65.93 -0.15% 2,871,096

End-of-day quote Shanghai S.E., May 21, 2024

More quotes
Beijing Wantai Biopharmaceutical Co., Ltd. is a company mainly engaged in the research and development, production and sales of in-vitro diagnostics. The Company produces and sells in-vitro diagnostics, in-vitro diagnostic equipment and vaccines. The Company is also engaged in the sales of agent products. The in-vitro diagnostics include: enzyme-linked immunosorbent assay (ELISA) reagents, chemiluminescence reagents, biochemical reagents and quality control products. The in-vitro diagnostic instruments mainly include the automatic chemiluminescence immunoassay analyzer. The primary product of vaccine products is Hecolin used for hepatitis E. The agent products are in-vitro diagnostics and in-vitro diagnostic equipment from Bio-Rad Laboratories Inc in the U.S. and Diagast SAS in France.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
65.63 CNY
Average target price
70.4 CNY
Spread / Average Target
+7.27%
Consensus
  1. Stock Market
  2. Equities
  3. 603392 Stock